Abstract

With the continuous development of cancer therapy, conventional animal models have exposed a series of shortcomings such as ethical issues, being time consuming and having an expensive cost. As an alternative method, microfluidic devices have shown advantages in drug screening, which can effectively shorten experimental time, reduce costs, improve efficiency, and achieve a large-scale, high-throughput and accurate analysis. However, most of these microfluidic technologies are established for narrow-range drug-concentration screening based on sensitive but limited flow rates. More simple, easy-to operate and wide-ranging concentration-gradient constructions for studying tumor cell–drug interactions in real-time have remained largely out of reach. Here, we proposed a simple and compact device that can quickly construct efficient and reliable drug-concentration gradients with a wide range of flow rates. The dynamic study of concentration-gradient formation based on successive spiral mixer regulations was investigated systematically and quantitatively. Accurate, stable, and controllable dual drug-concentration gradients were produced to evaluate simultaneously the efficacy of the anticancer drug against two tumor cell lines (human breast adenocarcinoma cells and human cervical carcinoma cells). Results showed that paclitaxel had dose-dependent effects on the two tumor cell lines under the same conditions, respectively. We expect this device to contribute to the development of microfluidic chips as a portable and economical product in terms of the potential of concentration gradient-related biochemical research.

Highlights

  • Cancer is widespread and affects one-third of the world’s population [1,2]

  • Th inlets and outlets of the microfluidic device were used for injection and elimination procedures. 16, 8 and 4 spiral mixers were connected in three circles (150 μm width; 50 μm height) respectively

  • We demonstrated a microfluidic device based on successive spiral mixer regulations that can be used for cell culture and drug screening

Read more

Summary

Introduction

Cancer is widespread and affects one-third of the world’s population [1,2]. It is a major public health problem worldwide [3]. Th routine drug development process for checking drug specificity and toxicity mainly involves drug screening in preclinical trials, in vitro platforms, and animal models [6,7,8]. These methods have certain limitations and cannot effectively mimic the microenvironment of tumor cell growth [9]. To significantly reduce the failure rate of clinical tumor trials and related costs of in vitro model preparation, it is necessary to develop a tumor model that is more time-saving, efficient, and low-cost

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call